Normal 0 false false false MicrosoftInternetExplorer4 Cell Therapeutics Inc (NASDAQ: CTIC) shares dipped 1.3% to $1.55. The company, on Jan. 18, said it will pay $19 million and adopt new corporate governance measures under a settlement that ends nearly three years of litigation with shareholders. The shareholder lawsuit had accused the Seattle-based biotech of not accurately disclosing information about Pixantrone, the company’s drug for non-Hodgkin lymphoma. Share volume was 86,000, compared to an all-day average of 339,000 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;}